Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Gilead Sciences

Pfizer

CRISPR Therapeutics is still in its early stages of growth. Gilead Sciences remains an underrated stock.

3 Dirt Cheap Stocks to Buy Right Now

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $49.49, denoting a -0.2% change from the preceding trading day.

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

CRISPR Therapeutics is in the process of building out a network of clinics. As those clinics open up, it'll be able to realize more revenue from its therapy.

Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?

CRISPR Therapeutics' stock may seem boring due to the slow FDA trial and rollout process, but it's a strong long-term investment. CASGEVY, their FDA-approved treatment for sickle cell disease and TDT, will generate revenue soon, with significant growth expected in 2025. The company's future potential lies in its pipeline for cardiovascular disease and cancer treatments, though these remain speculative.

Crispr Therapeutics: Prepare To Be Bored

CRISPR Therapeutics' lone approved product boasts multibillion-dollar revenue potential. Plus, this promising biotech could succeed in launching other breakthrough therapies.

1 Biotech Stock Down 62% to Buy and Hold

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $45.51, representing a +1.42% change from its previous close.

CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why

Amgen

Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair.

2 Biotech Bets to Buy in September

CRISPR recently obtained approval for Casgevy, a gene-editing therapy which may generate huge revenue. It could take years, however, before the biotech's bottom line starts to show significant improvement.

Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?

Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?

Iovance Biotherapeutics

Iovance Biotherapeutics is seeing its sales ramp up for the first time. CRISPR Therapeutics has also started to bring in solid revenue.

3 Monster Biotech Stocks to Buy Before 2025

Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.

CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?

CRISPR Therapeutics' stock has been volatile, with cautious optimism following FDA approval for gene therapy targeting sickle cell disease. Q2 2024 earnings revealed slow commercialization of Casgevy, with revenues significantly below expectations. Financial health of CRISPR is strong, with over 5 years of cash runway, but stock performance has lagged behind S&P 500 returns.

Crispr's Casgevy Launch: Promising Start, Uncertain Future

Beam Therapeutics

Intellia Therapeutics

Gene editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. It could help treat the 7,000 diseases caused by genetic disorders, most of which occur with gene mutation.

3 Gene Editing Stocks with Potential to Transform Medicine

Allogene Therapeutics Inc

Blueprint Medicines

Precision Biosciences

REGENXBIO

Sarepta Therapeutics

Voyager Therapeutics

With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.

7 Biotech Stocks to Buy for Their Game-Changing Potential

Crispr Therapeutics AG reported no revenues from Casgevy in Q2 earnings, but noted positive progress with over 35 authorized treatment centers activated globally. Casgevy's complex treatment journey involves a lengthy process with no revenue recognition until the end, but the therapy has shown high effectiveness in clinical studies. Crispr Therapeutics and Vertex are working on reducing preconditioning burden for Casgevy patients and exploring the potential of in vivo therapies for the future.

Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential

Alnylam Pharmaceuticals

Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030.

The 3 Best Gene Editing Stocks to Buy in August 2024

CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.

CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.49 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to loss of $0.98 per share a year ago.

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates

-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July-

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

CRISPR Therapeutics' first approval should go on to become massively successful. This approval was a major breakthrough in the area of gene editing.

Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker

Archer Aviation

Alarm.com

AeroVironment

DraftKings

Harmonic

Iridium Communications

Kratos Defense & Security Solutions

Rocket Lab USA

Big tech stocks cooled off in July, while smaller growth companies rallied. An anticipated rate cut could amplify this trend reversal in August and beyond.

10 Best Small and Mid-Cap Stocks to Consider Buying in August

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

Block

Trade Desk

Investing guru Cathie Wood still attracts a large following. Although the founder of the Ark Invest family of exchange-traded funds (ETFs) is trailing the market by a wide margin in 2024.

The Top 3 Cathie Wood Stocks to Buy Now: Summer 2024

CRISPR Therapeutics (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $57.92, signifying a +0.61% move from its prior day's close.

News for CRISPR Therapeutics Stock (CRSP)